Wall Street brokerages expect PDL BioPharma Inc (NASDAQ:PDLI) to report earnings per share (EPS) of $0.03 for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for PDL BioPharma’s earnings. PDL BioPharma posted earnings of $0.01 per share in the same quarter last year, which suggests a positive year over year growth rate of 200%. The business is scheduled to issue its next quarterly earnings report after the market closes on Thursday, March 8th.
On average, analysts expect that PDL BioPharma will report full-year earnings of $0.60 per share for the current fiscal year. For the next financial year, analysts forecast that the firm will post earnings of $0.10 per share. Zacks’ earnings per share calculations are an average based on a survey of research firms that follow PDL BioPharma.
PDLI has been the topic of several research reports. ValuEngine raised PDL BioPharma from a “hold” rating to a “buy” rating in a research report on Saturday, November 25th. BidaskClub lowered PDL BioPharma from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Zacks Investment Research lowered PDL BioPharma from a “buy” rating to a “hold” rating in a research report on Monday, January 8th. Finally, Cowen reaffirmed a “hold” rating and issued a $3.00 target price on shares of PDL BioPharma in a research report on Friday, October 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $3.33.
PDL BioPharma (NASDAQ:PDLI) opened at $2.48 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.16 and a quick ratio of 3.10. The firm has a market capitalization of $375.04, a price-to-earnings ratio of 4.86 and a beta of 0.48. PDL BioPharma has a 52-week low of $1.96 and a 52-week high of $3.55.
About PDL BioPharma
PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.